Business Wire

Kite Pharma and Vitruvian Networks Enter Strategic Partnership to Develop Best-In-Class Logistics and Data Analytics Software for Engineered T-cell Therapies at Commercial Scale

SANTA MONICA, Calif. and SAN FRANCISCO--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq: KITE) and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company ...
Yahoo Finance

Kite Pharma cell therapy plant in Urbana gets FDA approval for commercial production

Apr. 20—Kite Pharma's Urbana cell therapy manufacturing facility has received federal approval for commercial production of its treatment for blood cancer, the global biopharmaceutical company ...
Nasdaq

Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production

(RTTNews) - Biopharmaceutical company Kite, a Gilead Sciences, Inc. (GILD) company, announced Monday that the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) ...
Business Insider

Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel

IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), today announced that Kite Pharma has chosen Cryoport's industry-leading, advanced technology ...
Seeking Alpha

Kite Pharma teams up with Vitruvian Networks to create software to support commercial T-cell therapies

Kite Pharma (NASDAQ:KITE-1.3%) inks an strategic partnership with Vitruvian Networks, a cell and gene therapy software and analytics platform company formed by GE Ventures and the Mayo Clinic, to ...
The Globe and Mail

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, ...